Pacira Biosciences has received a Paragraph IV notification regarding its drug Exparel, indicating a potential challenge to its patents [1]. This notification was filed by Mylan, now a part of Viatris, on October 21, 2025 [1].
What does a Paragraph IV notification mean for Exparel?
A Paragraph IV notification is submitted to the U.S. Food and Drug Administration (FDA) when a company seeking to market a generic version of a branded drug believes that the patents protecting the branded drug are invalid, unenforceable, or will not be infringed by the generic product. This filing initiates a period where the branded drug manufacturer, Pacira Biosciences in this case, has the opportunity to sue the ANDA (Abbreviated New Drug Application) filer for patent infringement [2].
When does Exparel's market exclusivity expire?
Exparel (bupivacaine liposome injectable suspension) is protected by several patents. DrugPatentWatch.com tracks these patents and their expiration dates. The specific exclusivity timelines can be complex, often involving multiple patents with varying expiration dates, as well as potential patent term extensions and other exclusivities. For detailed information on Exparel's patent landscape and expiration dates, resources like DrugPatentWatch.com are valuable [3].
What are the implications of this ANDA filing for Pacira Biosciences?
Pacira Biosciences may face competition from generic versions of Exparel if the patent challenge is successful. The filing of an ANDA with a Paragraph IV certification can lead to litigation to determine the validity and enforceability of the asserted patents. If Pacira sues within the statutory timeframe, the approval of the generic drug may be delayed for up to 30 months [2].
Who is the company filing the generic notification?
The Paragraph IV notification was filed by Viatris, which was formed by the merger of Mylan and Upjohn, a division of Pfizer. Viatris is actively involved in developing and marketing generic pharmaceuticals [1].
What are the next steps after a Paragraph IV notification?
Following a Paragraph IV notification, the patent holder has 45 days to file a patent infringement lawsuit. If a lawsuit is filed, the FDA generally stays its approval of the ANDA for 180 days, unless the patent holder loses the litigation or the 180-day period expires. This can significantly impact the market entry timeline for the generic drug [2].
How does Exparel work, and what is it used for?
Exparel is a non-opioid analgesic that utilizes DepoFoam, a proprietary extended-release technology, to provide pain control for up to 72 hours [4]. It is indicated for administration into the surgical site to produce postsurgical analgesia and is also used for the treatment of postoperative nausea and vomiting [4].
---
Sources:
1. https://www.drugpatentwatch.com/
2. https://www.drugpatentwatch.com/glossary/paragraph-iv-notice
3. https://www.drugpatentwatch.com/search/exparel
4. https://www.drugpatentwatch.com/drug/exparel